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Gliomas are the most frequently occurring central nervous system
(CNS) tumours and include astrocytomas, anaplastic astrocytomas
and glioblastoma multiforme. They are severely disabling,
producing symptoms of headaches, fits, confusion, personality
changes and neurological deficits which impair the patients’
quality of life. Despite advances in the diagnosis and treatment of
gliomas the prognosis remains poor, with only 10–15% survival
for patients with high-grade gliomas at 30+ months (Brada et al,
1998). Nevertheless, considerable variation exists with respect to
post-operative survival. Identification of prognostic variables to
assist in clinical management is thus of considerable value to both
patients and clinicians.
Historically, prognostic models for gliomas have used clinical
variables and patient characteristics to determine factors that
predict response to therapy and survival. In 1990, the Medical
Research Council (MRC) working party developed a clinical
scoring system that predicted a better prognosis for patients less
than 45 years old at diagnosis, with longer duration of fits,
debulking surgery and a better performance status (Report of the
MRC Brain Tumour Working Party, 1990). Although adverse
histological features including high proliferative activity (Bruner,
1994), the presence of necrosis (Barker et al, 1996) and a gemisto-
cyte population of greater than 20% (Krouer et al, 1991) have been
identified in univariate analysis of small series, these have not
been evaluated in larger series and are not widely employed.
The development of gliomas, in common with many tumours, is
a multistep process involving the accumulation of several genetic
events which involve the activation of oncogenes (Collins, 1995)
and the loss of tumour suppressor genes (Jen et al, 1994; Louis and
Gusella, 1995; von Deimling et al, 1995). The commonest genetic
abnormality observed in gliomas is loss, often involving a whole
homologue, of chromosome 10 (Bigner at al, 1990). This loss is
associated with high-grade tumours, being rare in low-grade
astrocytomas but present in some 60–85% of high-grade gliomas
(Louis and Gusella, 1995). Recent studies have led to the
identification of at least three tumour suppressor genes, PTEN
(MMAC1), DMBT1 and LGI1 (Li et al, 1997; Mollenhauser et al,
1997; Steck et al, 1997; Chernova et al, 1998) on chromosome 10,
which may be involved in glioma progression. The aim of this
study was to determine whether loss of heterozygosity (LOH) for
chromosome 10 is an important prognostic variable in high-grade
gliomas and whether it provides additional predictive information
to the previously defined clinical prognostic indices.
MATERIALS AND METHODS
Patients
Between January 1994 and April 1997, blood samples and patho-
logical blocks of tumour material were collected prospectively
from 42 patients diagnosed with high-grade glioma. Blood tumour
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© 1999 Cancer Research Campaignpairs were obtained from a further 44 patients with high-grade
glioma who were being followed up in the oncology department
and for whom tumour blocks were available from the biopsy at
initial diagnosis.
Pathological diagnosis
Stained sections of tumour were examined by two independent
pathologists and tumours classified on the basis of criteria
described by Daumas-Duport et al (1998) including the presence
or absence of nuclear atypia, mitoses, endothelial proliferation and
necrosis. Where two of the first three criteria were present, almost
always nuclear atypia and mitosis, the tumours were categorized
as grade 3 or anaplastic astrocytomas (AA). If all three criteria
were present, the tumour was categorized as grade 4 or glioblas-
toma multiforme (GBM). Any tumour with necrosis, in addition to
one or more of the other three criteria, was classified as grade 4.
Of the 86 tumours examined, 36 were diagnosed as AA (grade 3)
and 50 as GBM (grade 4). Two cases of AA and one case of GBM
were subsequently excluded because DNA prepared from the
pathological blocks failed to amplify reproducibly.
Clinical variables
Clinical details including the age at diagnosis, gender, duration of
fits and nature of initial surgery were recorded for all patients.
Eastern Co-operative Oncology Group (ECOG) performance
status at diagnosis was prospectively recorded for 39 of 42 newly
diagnosed patients and was available for 35 of the 41 remaining
patients.
LOH for chromosome 10
DNA was prepared from blood samples using standard techniques.
Tumour tissue for DNA preparation was obtained from patho-
logical blocks of tumour removed at the time of initial surgery.
Microdissecton of glioma tissue from an unstained section was
performed by comparison with a consecutive section stained with
haematoxylin and eosin to distinguish areas of tumour from any
normal brain tissue. DNA was then prepared using a modification
of the method described by Wright and Manos (1990) (Fisher et al
1997).
A total of 50 ng of DNA, prepared from the patients blood and
1 ml tumour DNA were amplified using a control pair of primers
for one or more microsatellites on unrelated chromosomes, in
order to assess the quality of the tumour DNA. Blood–tumour
pairs were then amplified using a panel of six pairs of primers
which flank microsatellite repeat sequences on chromosome 10
(Figure 1). To facilitate analysis, one of each pair of primers was
labelled with the fluorescent dye FAM (blue) or HEX (green).
Polymerase chain reaction (PCR) products were subsequently
resolved either by electrophoresis in 6% denaturing polyacryl-
amide gels using an ABI 373A automated DNA sequencer
(Applied Biosystems Ltd, Cheshire, UK) or capillary electro-
phoresis using an ABI Prism 310 Genetic Analyser. Using ABI
672 or ABI Prism GeneScan software (Applied Biosystems Ltd),
sizes of fluorescent bands, representing different alleles, were
automatically determined by comparison with an internal size
standard. Where microsatellite polymorphisms were heterozygous
in the blood, the alleles present in the tumour were examined for
LOH. A small number of tumours were found to show allelic
imbalance rather than complete loss of one allele. In these cases,
the ratios of the height of the two alleles was calculated for the
blood (N1/N2) and tumour (T1/T2). Allelic imbalance was
calculated from the ratio of tumour signal to that of the normal
signal (T1/T2 over N1/N2). Ratios of < 0.67 or > 1.35 were taken
to indicate LOH for that locus.
Statistical methods
Survival was calculated from the day of diagnosis until death or
the date of last follow-up. Overall survival duration curves were
plotted according to the method of Kaplan and Meier (1958). The
log-rank method was used to test for the significance of differ-
ences in survival distributions (Peto et al, 1977). Multivariate
analysis of significant variables was performed using a stepwise
Cox regression model to establish which were independently prog-
nostic (Cox, 1972).
RESULTS
Clinicopathological details
Tumour samples have been analysed from 83 patients with high-
grade gliomas including 34 AA and 49 GBM. The median age of
patients at presentation was 49 years (range 17–78) and 50 were
male (60%). The performance status at presentation was recorded
prospectively for 73 patients and was ECOG grade 0 for six
patients (8%), grade 1 for 16 (22%), grade 2 for 30 (41%) and
grade 3 for 21 (29%). Initial surgery was biopsy alone for 46
(55%) and debulking surgery for 37 (45%). Sixty-nine patients
(83%) had whole brain irradiation following initial surgery.
Forty-three patients (51%) also received chemotherapy either as
adjuvant therapy or at relapse, including 38 who were enrolled
on trials of temozolomide (Newlands et al, 1996).
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Figure 1 Cytogenetic localization of microsatellite markers used to identify
LOH for chromosome 10 (GDB, 1998). The location of the tumour
suppressor genes, PTEN (MMAC1) (Li et al, 1997; Steck et al, 1997),
DBMT1 (Mollenhauser et al, 1997) and LGI1 (Chernova et al, 1998) are
shown in relation to the markers examinedTreatment outcome
The median overall survival from diagnosis is 1.24 years and the
1- and 2-year actuarial survival rates for the cohort are 63% (95%
confidence interval (CI) 52–74%) and 32% (95% CI 21–43%)
respectively. Patients with grade 3 tumours survived longer than
those with grade 4 tumours (log-rank, P < 0.0001) (Figure 2).
Patients who underwent debulking surgery lived no longer than
those who had only a biopsy (log-rank, P = 0.34). A better perfor-
mance status at presentation was also associated with a trend
towards longer survival although this failed to reach statistical
significance (log-rank, P = 0.056). There was no difference in
survival between the genders (log-rank, P = 0.50) or in relation to
duration of fits prior to diagnosis (proportional hazards, P = 0.39).
Younger patients survived longer (proportional hazards,
P < 0.0001).
LOH for chromosome 10
Genotype analysis revealed no loss (Figure 3A) for any of the loci
examined on chromosome 10 in 24 (29%) tumours. Of the
remaining 59 tumours, 41 (49% of all cases) demonstrated LOH
(Figure 3B) for all chromosome 10 loci tested, while 18 (22% of
all cases) had partial LOH, i.e. LOH for only some informative
loci. Partial LOH was confined to the long arm (10q) in six and the
short arm (10p) in three cases, whilst alleles from both arms were
lost in four cases (Figure 4). The five remaining tumours showed
heterogeneity with respect to LOH, in that some markers showed a
greater degree of loss within the tumour than others. This suggests
that for these five tumours, at least, two or more different cell
populations were present within the sample. Complete LOH for
chromosome 10 was observed more frequently in grade 4 (59%)
than grade 3 tumours (35%) while partial loss occurred at a higher
frequency in grade 3 (24%) than grade 4 (20%). No loss was more
frequently associated with grade 3 (38%) than grade 4 (22%)
tumours.
Prognostic factors
Within high grade tumours, any loss of chromosome 10 was asso-
ciated with a reduced overall survival (log-rank, P = 0.0001)
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Figure 2 Kaplan–Meier overall survival duration curves according to
tumour grade
Figure 3 Microsatellite polymorphisms detected following PCR amplification with primers for the dinucleotide repeats D10S212 in cases gli 44 and gli 4
respectively. Fluorescently labelled microsatellites are displayed as characteristic electropherogram peaks following gel electrophoresis. Sizes of alleles, in base
pairs (bps), are those calculated using GeneScan software. Variation of dinucleotide peak heights within samples represents preferential amplification of smaller
alleles. (A) The relative height of the two alleles in the tumour DNA is not significantly different to that in DNA from the blood, indicating no LOH for this locus in
the tumour. (B) DNA from the blood sample is heterozygous for the D10S212 microsatellite. However, the tumour DNA has only a single allele indicating LOH
(arrowed) for this locus
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AB(Figure 5). Median survival for patients with complete or partial
LOH for chromosome 10 was 0.99 years, while median survival
for patients without LOH for 10 was 2.9 years. There was a corre-
lation between any chromosome 10 loss and poorer performance
status at presentation (c2, P = 0.005), increasing age at diagnosis
(Mann-Whitney U-test, P = 0.029) and with tumour grade (c2,
P = 0.04) but not initial surgery (c2, P = 0.40). A Cox multivariate
model for survival duration identified age (hazard ratio (HR) =
1.04, 95% CI 1.02–1.06, P = 0.004), grade (HR = 0.34, 95%
CI 0.18–0.65, P = 0.001) and any loss of chromosome 10
(HR = 1.87, 95% CI 1.00–3.60, P = 0.050) as the only independent
prognostic variables.
When patients with grade 3 or grade 4 tumours were considered
independently, patients who had grade 3 tumours with LOH for
chromosome 10 showed a significantly reduced overall survival
(log-rank, P = 0.012) (Figure 6A), median survival for the two
groups being 1.5 years and 3.5 years respectively. For patients
with grade 4 tumours, with LOH or without LOH for chromosome
10, the median survival was 0.95 and 1.20 years respectively.
Although patients with grade 4 tumours with LOH showed shorter
overall survival, this did not achieve significance (log-rank,
P = 0.26) (Figure 6B).
DISCUSSION
The most frequently occurring central nervous system (CNS)
tumours, the astrocytic gliomas, have a very poor prognosis; high-
grade gliomas being almost universally fatal despite surgery,
radiotherapy and chemotherapy. Within this group of patients a
number of clinical and pathological variables have been examined
with respect to prognosis, the most significant prognostic variables
in other series being age at diagnosis, extent of surgery, clinical
performance status at time of diagnosis (Report of the MRC Brain
Tumour Working Party, 1990) and tumour grade (Chang et al,
1993).
In our series the extent of initial surgery did not affect survival.
While a better performance status at presentation was associated
with longer survival this did not reach significance. Multivariate
analysis confirmed age to be an independent prognostic variable,
in that younger patients survived longer. Similarly, tumour grade
was shown to be an independent prognostic variable, patients with
grade 4 tumours surviving for a significantly shorter period than
those with grade 3 tumours. The treatment offered to the cohort
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Figure 4 Thirteen cases in which partial LOH was identified. LOH for a locus is represented by (l) no LOH by (l l) and uninformative markers by (      )
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Figure 5 Kaplan–Meier overall survival duration curves for all patients
according to chromosome 10 status of the tumourfollowing initial surgery varied and both radiotherapy and
chemotherapy schedules have altered over the course of recruit-
ment. Therefore the influence of post-surgical treatments cannot
be reliably evaluated. It has been shown that adjuvant treatment
following surgery has little influence on median survival in
patients with high grade glioma (Brada et al, 1998). Variation in
treatment is therefore unlikely to significantly influence prognosis.
It has recently been suggested that some of the genetic changes,
associated with glioma development and progression, may have
prognostic significance. While amplification and loss of specific
regions of the genome have been found in a high proportion of
gliomas, not all tumours have been shown to have the same combi-
nation of genetic alterations. This variation may reflect distinct
molecular pathways of tumour progression (Louis and Gusella,
1995; von Deimling et al, 1995) and represent subgroups of
tumours with different prognosis.
Alterations of p53, frequently associated with tumours which
show progression through low- to high-grade and amplification of
the epidermal growth factor receptor (EGFR), associated with high
grade glioma which arise ‘de novo’, are two of the most commonly
observed genetic changes in glioma. However, the prognostic
significance of overexpression of the EGFR (Waha et al, 1996;
Zhu et al, 1996; Rainov et al, 1997) and mutations or aberrant
expression of p53 (Campomenosi et al, 1996; Cunningham et al,
1997; Korkolopoulou et al, 1997), remains equivocal.
The most frequently observed genetic alteration in high-grade
tumours is LOH for chromosome 10. Despite this a significant
proportion of high-grade gliomas show no LOH for chromosome
10 markers. Poor prognosis has been associated with abnormalities
of chromosome 10 (Ganju et al, 1994), while patients with p53
gene alteration in their tumour were found to have a significantly
shorter survival time if in addition they had complete LOH for
chromosome 10 (Leenstra et al, 1998). Our aim was to determine
whether LOH for chromosome 10 was in fact an independent
prognostic variable. The present study includes 83 patients with
high-grade tumours of whom 69 (83%) have been followed up
until death. Patients with either complete or partial loss of chromo-
some 10 showed a significantly reduced survival time compared to
those patients with no LOH for chromosome 10. Multivariate
analysis showed that this loss was independent of other prognostic
variables considered. When patients with grade 3 or grade 4
tumours were considered independently, grade 4 tumour cases
with LOH showed lower overall survival but this did not achieve
significance. This may reflect the relatively small number of cases
in this group which did not show any LOH. In patients with grade
3 tumours, LOH was associated with a significantly reduced
overall survival. Analysis of chromosome 10 loss is thus able to
identify a subgroup of patients with anaplastic astrocytomas who
have a very poor prognosis.
In common with other reports, most cases in our study with
LOH for chromosome 10, involved loss of the whole homologue.
Frequent loss of the whole homologue suggests the involvement of
several different tumour suppressor genes on chromosome 10 in
glioma development. This is confirmed by the observation that,
where partial loss is found, it does not always involve the same
region of the chromosome. Since the start of this study two novel
tumour suppressor genes, PTEN (MMAC1) (Li et al, 1997; Steck
et al, 1997) and DBMT1 (Mollenhauser et al, 1997) have been
identified on the long arm of chromosome 10. One of these, PTEN,
has been shown to be mutated in a proportion, but not all, glioma
with LOH for chromosome 10 (Rasheed et al, 1997; Bostrom et al,
1998, Fults et al, 1998). Although DBMT1 maps to a region,
10q25–26, which is more frequently associated with LOH in high-
grade gliomas (Rasheed et al, 1995), it is also deleted in less than
25% of GBM, suggesting that other significant tumour suppressor
genes on chromosome 10 may also be involved in glioma progres-
sion. A third candidate tumour suppressor gene, LGI1 (Chernova
et al, 1998) has now been identified at 10q24.
Recently Lin et al (1998) have shown that patients with
anaplastic astrocytomas or glioblastoma multiforme which show
LOH for the region of chromosome 10 around the PTEN
(MMAC1) locus have a significantly worse prognosis than
patients with no LOH for this region. In their study LOH around
the DMBT1 locus had no prognostic significance. In our study,
most patients showing LOH for chromosome 10 showed loss of
the whole chromosome. In four of the 13 cases with loss of only
part of chromosome 10, the marker D10S608 was lost (Figure 4),
suggesting that loss of function of PTEN might be involved in
these cases. Seven cases showed partial loss involving 10p
(Figure 4). In three of these the LOH was confined to markers on
10p. This supports the hypothesis that at least one further tumour
suppressor gene may be present on the short arm of chromosome
Prognostic factors in high-grade gliomas 1375
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Figure 6 Kaplan–Meier overall survival duration curves according to
chromosome 10 status of the tumour in patients with (A) grade 3 and
(B) grade 4 tumours10. In cases showing partial LOH involving 10p, all three markers
on 10p were lost in one case. Two cases were uninformative with
respect to the extent of LOH on 10p. However, four cases showed
LOH which was confined to the distal region of chromosome 10,
confirming recent data which assigns putative tumour suppressor
genes on 10p to the 10p14 and 10p15 regions (Voesten et al, 1997;
Ichimura et al, 1998; Kon et al, 1998). Refinement of these regions
of loss should lead to the identification of novel tumour suppressor
genes involved in glioma progression.
We have shown that LOH for chromosome 10 is an independent
prognostic variable in patients with high-grade glioma. Further
studies are required to identify novel tumour suppressor genes on
chromosome 10 and determine the relative prognostic significance
of these and known tumour suppressor genes in patients with
high-grade glioma.
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